MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2017 International Congress

    Clinical and Imaging and phenoconversion in the PARS prodromal cohort

    K. Marek, A. Siderowf, S. Eberly, D. Oakes, M. Stern, D. Russell, J. Seibyl, D. Jennings (New Haven, CT, USA)

    Objective: We report clinical and imaging phenoconversion data at 6 years follow-up for the PARS cohort. Background: The PARS cohort consists of 203 hyposmic and…
  • 2017 International Congress

    Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes

    M. Asanuma, I. Miyazaki, R. Kikuoka, S. Murakami, N. Isooka, Y. Kitamura (Okayama, Japan)

    Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…
  • 2017 International Congress

    Higher genetic load is associated with an earlier disease onset but not with more rapid disease progression in Parkinson’s disease

    S. Lerche, I. Wurster, B. Roeben, E. Schaeffer, C. Schulte, S. Akbas, A.-K. Hauser, C. Deuschle, T. Gasser, D. Berg, K. Brockmann (Tuebingen, Germany)

    Objective: To evaluate the influence of genetic variants on phenotypic variability and disease progression in PD patients. Background: Parkinson’s disease (PD) patients show a large…
  • 2017 International Congress

    The Corticobasal Degeneration Functional Rating Scale (CBD-FS)

    A. Lang, G. Stebbins, A. Boxer (Toronto, Canada)

    Objective: To develop a patient/care giver-reported scale that is capable of assessing functional disability in CBD that can be easily and reliably used in clinical…
  • 2017 International Congress

    WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study

    D. Bega, A. Ala, F. Askari, J. Bronstein, A. Czlonkowska, P. Ferenci, D. Nicholl, K.-H. Weiss, M. Schilsky (Chicago, IL, USA)

    Objective: The objective of this study was to evaluate the efficacy and safety of 24 week WTX101 treatment in newly diagnosed Wilson Disease (WD) patients. Background:…
  • 2017 International Congress

    Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study

    K. Dashtipour, Z. Mari, J. Jankovic, C. Adler, M. Schwartz, M. Brin (Loma Linda, CA, USA)

    Objective: To explore minimal clinically important change perceived by patients as beneficial by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) using data from the…
  • 2017 International Congress

    Physical Activity in Early Parkinson Disease

    S. Mantri, M. Fullard, J. Duda, J. Morley (Philadelphia, PA, USA)

    Objective: To characterize physical activity habits in patients with early Parkinson disease (PD). Background: Physical activity is an important therapy for PD as it may…
  • 2017 International Congress

    Preventing Levodopa Induced Dyskinesia with Docosohexanoid Acid in Parkinson Disease

    K. Chung, B. Lobb (Portland, OR, USA)

    Objective: The purpose of this study was to determine if Docosohexanoic acid (DHA) affects the speed and severity of development of levodopa induced dyskinesia (LID) in subjects starting levodopa (LD).…
  • 2017 International Congress

    Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis

    C. Tarolli, K. Andrzejewski, M. Bull, S. Goldenthal, M. O'Brien, T. Simuni, G. Zimmerman, K. Biglan, E.R. Dorsey (Rochester, NY, USA)

    Objective: To demonstrate the feasibility, reliability, and value of conducting web-based clinical trial assessments in individuals with Parkinson disease (PD). Background: Increasing interest has been…
  • 2017 International Congress

    Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

    B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

    Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29509 (not found)
  • Expanding the Phenotype of KCNA2 Mutation: Tics and Stereotypies
  • #22661 (not found)
  • #29591 (not found)
  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley